Enanta Pharmaceuticals, Inc. (9EP.F)
| Previous close | 12.70 |
| Open | 12.60 |
| Bid | 12.70 x 15600 |
| Ask | 12.80 x 15300 |
| Day's range | 12.60 - 12.60 |
| 52-week range | 7.50 - 33.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 266.839M |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.13 |
| Earnings date | 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 65.33 |
Business WireEnanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WATERTOWN, Mass., April 30, 2024--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that effective April 29, 2024, the Compensation Committee of Enanta Pharmaceuticals’ Board of Directors granted employment inducement awards to Matthew P. Kowalsky, Enanta’s new Chief Legal Officer, consisting of a non-qualified stock option to purchase 150,000 shares of its common
Business WireEnanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer
WATERTOWN, Mass., April 30, 2024--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight.
Business WireEnanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024
WATERTOWN, Mass., April 29, 2024--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2024, after the U.S. market closes on May 6, 2024. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, includin
